初治弥漫大B细胞淋巴瘤患者hsa-miR-23a、hsa-miR-566表达水平及其临床意义

目的〖KG*2〗探讨初治弥漫大B细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）患者hsa-miR-23a 、hsa-miR-566表达水平及其临床意义。〖HTH〗方法〖KG*2〗选取60例初治DLBCL患者作为观察组，60例健康人群作为对照组。检测2组外周血hsa-miR-23a、hsa-miR-566表达水平并对比其差异。分析hsa-miR-23a、hsa-miR-566表达水平与DLBCL临床特征及预后的关系。〖HTH〗结果〖KG*2〗观察组hsa-miR-23a-3p、hsa-miR-566表达水平均高于对照组，差异有统计学意义（P＜0.05）。外周血hsa-miR-23a-3p、hsa-miR-566表达水平与肿瘤分期、淋巴结区受累数、国际预后指数（international prognostic index，IPI）积分相关（P均＜0.05）。以DLBCL患者外周血hsa-miR-23a-3p、hsa-miR-566表达水平均数3.35、1.69作为临界值，将患者分为hsa-miR-23a-3p高表达组（32例）、hsa-miR-23a-3p低表达组（28例）；hsa-miR-566高表达组（29例）、hsa-miR-566低表达组（31例）。hsa-miR-23a-3p高表达组3年总生存率为40.63%（13/32）明显低于低表达组的67.86%（19/28），差异有统计学意义（χ2 =4.450，P=0.035）；hsa-miR-23a-3p高表达组、hsa-miR-23a-3p低表达组的中位生存时间分别为26.73个月和32.52个月（P＜0.01）。hsa-miR-566高表达组3年总生存率为37.93%（11/29）明显低于低表达组的67.74%（21/31），差异有统计学意义（χ2=5.350，P=0.021）；hsa-miR-566高表达组、hsa-miR-566低表达组的中位生存时间分别为27.45个月和32.35个月（P＜0.01）。〖HTH〗结论〖KG*2〗初治DLBCL患者外周血hsa-miR-23a-3p、hsa-miR-566均呈高表达，且与DLBCL患者临床分期、淋巴结区受累数、IPI指数及预后密切相关，有望成为DLBCL诊断的重要标记物。

Expression and clinical significance of hsa-mir-23a and hsa-mir-566 in patients with newly diffuse large B cell lymphoma

ObjectiveTo explore the expression levels of hsa-miR-23a and hsa-miR-566 in patients with newly diffuse large B cell lymphoma(DLBCL) and their clinical significance. MethodsSixty cases of newly DLBCL patients were selected as the observation group, and 60 cases of healthy people as the control group. The expression levels of hsa-mir-23a and hsa-mir-566 in peripheral blood of the two groups were detected and compared. The relationship between the expression level of hsa-mir-23a and hsa-mir-566 and the clinical characteristics and prognosis of DLBCL were analyzed. ResultsThe expression levels of sa-mir-23a-3p and hsa-mir-566 in the observation group were higher than those in the control group, The difference was statistically significant(P＜0.05). The expression levels of hsa-miR-23a-3p and hsa-miR-566 in peripheral blood were related to tumor stage, number of lymph node metastasis, and international prognostic index(IPI) points(all P＜0.05). The mean expression levels of hsa-mir-23a-3p and hsa-mir-566 in peripheral blood of DLBCL patients were 3.35 and 1.69 as critical values. The patients were divided into hsa-mir-23a-3p high expression group(32 cases), hsa-mir-23a-3p low expression group(28 cases), hsa-mir-566 high expression group(29 cases) and hsa-mir-566 low expression group(31 cases). The overall survival rate of hsa-mir-23a-3p high expression group was 40.63%(13/32), which was significantly lower than 67.86%(19/28) of low expression group, The difference was statistically significant(χ2=4.450, P=0.035)； The median survival time of hsa-mir-23a-3p high expression group and hsa-mir-23a-3p low expression group were(26.73 months vs 32.52 months, P＜0.01). The overall survival rate of hsa-mir-566 high expression group was 37.93%(11/29), which was significantly lower than 67.74%(21/31) of low expression group. The difference was statistically significant(χ2=5.350, P=0.021). The median survival time of hsa-mir-566 high expression group and hsa-mir-566 low expression group were(27.45 months vs 32.35 months，P＜0.01). ConclusionThe expression of hsa-mir-23a-3p and hsa-mir-566 in the peripheral blood of patients with newly DLBCL is high, which is closely related to the clinical stage, the number of lymph node metastasis, IPI index and prognosis of patients with DLBCL, and is expected to become an important marker in the diagnosis of DLBCL.